Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Debt to Equity (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Debt to Equity for 16 consecutive years, with $2.61 as the latest value for Q4 2025.

  • Quarterly Debt to Equity rose 347.64% to $2.61 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.61 through Dec 2025, up 347.64% year-over-year, with the annual reading at $2.61 for FY2025, 347.64% up from the prior year.
  • Debt to Equity for Q4 2025 was $2.61 at Harvard Bioscience, up from $2.41 in the prior quarter.
  • The five-year high for Debt to Equity was $2.61 in Q4 2025, with the low at $0.5 in Q4 2023.
  • Average Debt to Equity over 5 years is $0.95, with a median of $0.59 recorded in 2024.
  • The sharpest move saw Debt to Equity decreased 23.78% in 2023, then surged 368.38% in 2025.
  • Over 5 years, Debt to Equity stood at $0.58 in 2021, then rose by 11.88% to $0.65 in 2022, then decreased by 22.83% to $0.5 in 2023, then increased by 16.61% to $0.58 in 2024, then skyrocketed by 347.64% to $2.61 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $2.61, $2.41, and $2.22 for Q4 2025, Q3 2025, and Q2 2025 respectively.